Heartflow’s Chief Medical Officer Executes Balanced 10b‑5‑1 Trades, Buying at 52‑Week Low and Selling Near Premium—Insider Confidence Signals Steady Outlook.

Insider Activity Spotlight: Rogers Campbell’s Recent Moves at HEARTFLOW

In the latest 4‑form filing dated July 15, 2026, Chief Medical Officer Rogers Campbell executed a Rule 10b5‑1 trading‑plan transaction: he purchased 9,219 shares at $19.00 and simultaneously sold an equal number of shares at $25.72. The net effect was a modest increase in his holdings to 97,950 shares, a figure that represents roughly 4% of the company’s outstanding shares. The simultaneous buy‑sell pattern—common to 10b5‑1 plans—suggests Campbell is following a pre‑established schedule rather than reacting to short‑term price movements.

What Does This Mean for Investors? The price at which Campbell bought the shares ($19) sits near the 52‑week low of $20.13, whereas the sale price ($25.72) is still below the current market close of $25.97. This dual activity can be read as a balanced approach to portfolio management: acquiring shares at a discount while divesting at a modest premium. For investors, it signals a confidence that the company’s valuation is poised for a rebound, yet it also hints that the medical‑technology firm remains within a volatility envelope that warrants cautious optimism.

A Snapshot of Campbell’s Trading Pattern Campbell’s insider history is characterized by a series of 10b5‑1‑based purchases and sales that cluster around key corporate milestones. Over the past four months, he has traded roughly 50,000 shares, alternating between buying near the low end of the price range (as low as $8.33) and selling around $25–$30. This pattern aligns with a disciplined, time‑based plan rather than opportunistic trades. Moreover, his option activity—selling 10,000 options on July 15—indicates a willingness to monetize potential upside while still retaining a significant equity stake.

Implications for HEARTFLOW’s Future The company’s recent performance—a 6.89% weekly decline and a 24.24% monthly drop—suggests a market correction, yet the underlying AI‑driven platform remains a strategic asset in the competitive coronary artery disease sector. Insider confidence, as reflected in Campbell’s balanced trades, may assuage concerns about a lack of leadership backing. However, the sustained sell pressure from other executives, notably CEO Farquhar’s recent sales, could temper that sentiment.

Bottom Line for Investors Rogers Campbell’s latest 10b5‑1 transactions underscore a measured, plan‑driven approach to equity management. While they do not signal an immediate strategic shift, they do provide a window into how the company’s medical leadership views the firm’s valuation trajectory. Investors should watch for subsequent market moves and corporate developments—particularly any new product launches or partnership announcements—that could justify a reevaluation of HEARTFLOW’s stock, and keep an eye on the broader health‑tech landscape that could influence the company’s long‑term upside.